
## **TFIIS Antibody**

5	fied Protei 2–240A Genel 2–240A–1		NP_006747.1 6917	BETHYL LABORATORIES, INC	
APPLICATIONS	WB, IHC				
SPECIES REACTIVITY	Human, Mouse				
PRESUMED REACTIVIT	Y Based on 100% sequen	ce ide	ntity, this antibody is predicted	to react with Rat and Bovine	
AMOUNT	100 µl	100 µl			
CONCENTRATION	NTRATION 200 µg/ml				
STORAGE/SHELF LIFE	2 – 8° C / 1 year from c	2 – 8° C / 1 year from date of receipt			
PHYSICAL STATE	Liquid				
BUFFER	Tris-buffered Saline co	Tris-buffered Saline containing 0.1% BSA and 0.09% Sodium Azide			
ISOTYPE	IgG	IgG			
ORIGIN	USA				
PRODUCTION PROCEDURES	Antibody was affinity purified using an epitope specific to TFIIS immobilized on solid support.				
FROCEDURES	The epitope recognized by A302–240A maps to a region between residue 200 and 250 of human transcription elongation factor S–II (transcription elongation factor A (SII), 1) using the numbering given in entry NP_006747.1 (GeneID 6917).				
	Immunoglobulin concentration was determined by extinction coefficient: absorbance at 280 n of 1.4 equals 1.0 mg of IgG.				
APPLICATIONS Centrifuge tube to remove product from lid. Optimal working dilutions should be determined experimentally by the investigator. Prepare working dilution immediately before use.					
	Western Blot	1:2	2,000 - 1:10,000		
	Immunoprecipitation	No	t recommended. Use rabbit anti	-TFIIS antibody A302-239A.	
	Immunohistochemistry		200 – 1:1,000. Epitope retrieval commended for FFPE tissue sect		
APPLICATION NOTES	Western blot of lysates	Western blot of lysates performed using standard western blot reagents and 4-20% SDS-PAGE.			
IHC HUMAN CONTRO	Breast Carcinoma, Ovarian Carcinoma, Prostate Carcinoma				
ADDITIONAL INFO		https://www.bethyl.com/product/A302-240A Use the link above to view SDS, a current list of citations, and other product specific information.			


This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc. Eric McIntush, PhD | Chief Scientific Officer Date: June 21, 2019

Bethyl Laboratories, Inc. • 25043 West FM 1097 • Montgomery, TX 77356 • 800.338.9579 • 936.597.6111 • 866.597.6105 (FAX) • www.bethyl.com • technical@bethyl.com

For in vitro laboratory use only. Not for any clinical, therapeutic or diagnostic use in humans or animals. Not for human or animal consumption. This product may not be resold or modified for resale without the prior written approval of Bethyl Laboratories, Inc. The information provided in this data sheet is believed to be correct but does not purport to be all-inclusive and is intended to be used as a guide. Bethyl Laboratories, Inc. shall not be liable or responsible in any way for use of either this information or the material supplied. Disposal of hazardous material may be subject to federal, state or local laws or regulations.



Detection of human and mouse TFIIS by western blot (h&m) and immunoprecipitation (h). *Samples:* Whole cell lysate from HeLa (5, 15 and 50 µg for WB; 1 mg for IP, 20% of IP loaded), HEK293T (T; 50 µg) and mouse NIH 3T3 (M; 50µg) cells. *Antibodies:* Affinity purified rabbit anti-TFIIS antibody A302-240A used for WB at 0.04 µg/ml (A) and 1 µg/ml (B) and used for IP at 10 µg/mg lysate. TFIIS was successfully immunoprecipitated by rabbit anti-TFIIS antibody A302-239A, which recognizes an upstream epitope. *Detection:* Chemiluminescence with exposure times of 3 minutes (A) and 10 seconds (B).



Detection of human TFIIS by immunohistochemistry. Sample: FFPE section of human breast carcinoma. Antibody: Affinity purified rabbit anti- TFIIS (Cat. No. A302-240A Lot1) used at a dilution of 1:1,000 (0.2µg/ml). Detection: DAB